Average Price Target: $31.71
▲ +108.92% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $31.71, with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 108.92% upside from the last price of $15.18.
The current consensus among 8 investment analysts is to buy stock in Chinook Therapeutics.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.